Full-Time

Windows Device Engineering Lead

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$137k - $215.3k/yr

+ Short-term incentives + Long-term incentives + 401(k) match + Tuition reimbursement

Cambridge, MA, USA

In Person

Occasional travel may be required, estimated at 0–10% annually.

Category
IT Operations
Required Skills
PowerShell
Microsoft Azure
LDAP
Git
ServiceNow
Microsoft Windows
Microsoft Intune
SCCM
Vulnerability Analysis
iOS/Swift
Android Development
DevOps

Get referred to Takeda

See people who can refer or advise you

Requirements
  • At least 7 years of hands-on experience in Windows endpoint management at enterprise scale, supporting 10,000 or more endpoints.
  • Experience managing a globally distributed Windows device fleet across multiple geographies.
  • At least 3 years of experience directly leading or coordinating technical teams, including offshore or nearshore resources.
  • Deep, hands-on expertise in Microsoft Intune, including device enrollment, configuration profiles, compliance policies, application deployment, update rings, co-management, and tenant-attach scenarios.
  • Strong working knowledge of SCCM/MEMCM site design, client deployment, task sequences, operating system deployment, software update management, and reporting with SSRS.
  • Advanced PowerShell scripting ability, including production-grade scripts, Intune, Microsoft Graph, Active Directory, and Windows management modules, error handling, logging, and modular script design.
  • Proficiency with Win32 application packaging for Intune, IntuneWinAppUtil, MSI/MSIX repackaging, silent install parameters, detection rules, dependency management, SCCM packages, and task sequences.
  • Working knowledge of CIS Microsoft Windows Benchmark controls and experience translating CIS controls into Intune/SCCM policies and tracking compliance.
  • Experience deploying and managing Microsoft Defender for Endpoint at scale, including onboarding, policy configuration, attack surface reduction rules, threat and vulnerability management, and integration with Microsoft Sentinel or SIEM platforms.
  • Availability to overlap with India-based contractor teams for daily stand-ups and escalations, with early-morning or late-afternoon flexibility.
  • Participation in an on-call rotation for critical P1/P2 endpoint incidents and change windows.
  • Willingness to travel occasionally for team on-sites or major project deployments.
  • Ability to operate in a geographically distributed enterprise IT environment with competing priorities.
Responsibilities
  • Architect, maintain, and continuously improve the global Windows device management platform using Microsoft Intune and SCCM/MEMCM.
  • Define and own configuration baselines, enrollment profiles, compliance policies, and conditional access rules across approximately 50,000 endpoints.
  • Drive modernization toward cloud-native device management using Autopilot, Intune-only, and co-management approaches.
  • Oversee device lifecycle management, including provisioning, imaging, refresh cycles, and decommissioning.
  • Own the end-to-end monthly Patch Tuesday cycle, including planning, ring-based deployment, remediation tracking, and executive reporting.
  • Manage software update servicing through WSUS/SUP, Intune Update Rings, and Windows Autopatch, ensuring service-level agreement compliance across global regions.
  • Partner with Security Operations to remediate critical and high vulnerabilities within agreed service-level objective windows.
  • Maintain a documented patching runbook and escalation path for failures and exceptions.
  • Implement and enforce Level 1 and Level 2 CIS Benchmark controls for Windows through Intune configuration profiles and SCCM baselines.
  • Own Microsoft Defender for Endpoint deployment, configuration, and health monitoring, including onboarding policies, attack surface reduction rules, tamper protection, and threat and vulnerability management.
  • Collaborate with Security to operationalize Microsoft Defender for Endpoint alerts, Secure Score improvements, and endpoint detection and response posture.
  • Conduct periodic compliance reporting against CIS benchmarks, remediate drift, and maintain audit-ready documentation.
  • Manage and tune Intune compliance and conditional access policies to enforce Zero Trust principles.
  • Develop, maintain, and peer-review PowerShell scripts for compliance remediation, reporting, inventory, and configuration drift detection.
  • Build and maintain continuous integration and continuous delivery-friendly script repositories with version control, testing frameworks, and documentation standards.
  • Use Graph API and the PowerShell software development kit for Intune to automate tenant configuration, bulk operations, and reporting.
  • Champion scripting best practices and provide guidance and code reviews to contractor team members.
  • Lead application packaging efforts for Win32 applications in Intune, MSI/EXE/MSIX transforms, and SCCM packages/task sequences.
  • Define and maintain application packaging standards, testing procedures, and approval workflows.
  • Manage the application catalog to keep software current, licensed, and securely deployed.
  • Coordinate with software vendors and internal stakeholders to resolve packaging challenges and dependency conflicts.
  • Lead, coordinate, and quality-assure the work of offshore contractors based primarily in India, including task assignment, sprint planning, and performance feedback.
  • Establish service-level agreements, runbooks, and escalation paths to ensure consistent delivery quality across time zones.
  • Conduct regular stand-ups, knowledge-transfer sessions, and technical mentorship for the contractor team.
  • Manage staffing levels, onboarding, and knowledge continuity to minimize single points of failure.
  • Collaborate with IT leadership to prioritize the team's backlog against project and operational demands.
  • Maintain comprehensive documentation for device management processes, configurations, and operational procedures.
  • Produce regular management reporting on endpoint health, patch compliance, security posture, and key performance indicators.
  • Participate in change management processes and ensure endpoint-platform changes are risk-assessed and communicated.
  • Represent the endpoint team in cross-functional meetings with IT Security, Networking, Help Desk, and business units.
Desired Qualifications
  • Prior experience working within a 24/7 global IT operations model is preferred.
  • Experience migrating workloads to Intune is preferred.
  • Microsoft 365 Certified: Endpoint Administrator Associate (MD-102) or equivalent certification is preferred.
  • Microsoft Certified: Security, Compliance, and Identity Fundamentals or Security Operations Analyst Associate (SC-200) certification is preferred.
  • Experience in highly regulated industries such as financial services, healthcare, or government is preferred.
  • Familiarity with additional endpoint security tools such as Microsoft Defender, CrowdStrike, or Tanium is preferred.
  • Exposure to non-Windows platforms, including macOS and iOS/Android via Intune, in a mixed-OS environment is preferred.
  • Experience with software license management and hardware asset management processes is preferred.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval for MIMRYLO unlocks near-term U.S. oncology revenue.
  • Takeda expects ORZEYFUL U.S. launch by November 2026, pending DEA scheduling.
  • Q1 FY2026 new launches grew 22.6%, offsetting mature-brand declines and supporting guidance.

What critics are saying

  • May 18, 2026 AMITIZA verdict exposed Takeda to $2.6 billion treble-damage risk.
  • Takeda plans 4,500 FY2026 cuts, signaling launch execution pressure and organizational churn.
  • Patent erosion crushed VYVANSE sales 60.7% at constant currency in Q1 FY2026.

What makes Takeda unique

  • ORZEYFUL became the first orexin agonist approved for narcolepsy type 1 in 2026.
  • MIMRYLO offers first-in-class hepcidin mimetic therapy for polycythemia vera after FDA approval.
  • Takeda pairs global scale with Japanese discovery, including Shonan-led neurology innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Sep 9th, 2026
Trialbee unveils AI-powered patient screening chatbot at DPHARM 2026

Trialbee, a patient recruitment platform provider, will present at DPHARM 2026 in Boston on 15-16 September. The Swedish-American company will unveil AI-powered patient screening in its Honey Platform, enabling conversational AI chatbots to conduct initial candidate assessments whilst giving patients the option to speak with recruitment specialists. Trialbee will present jointly with pharmaceutical company Takeda on integrating their respective platforms to build research-ready patient communities that extend beyond single trials. The company will also participate in a panel discussing AI applications at clinical trial sites. The Honey Platform has added several AI features this year, including candidate summaries, duplicate detection, and recruitment data analysis. Trialbee supports over 6,000 research sites across 50 countries and reports a 91% repeat business rate with biopharmaceutical companies.

Associated Press
Sep 9th, 2026
Onco360 selected as specialty pharmacy partner for rare blood cancer drug MIMRYLO

Onco360, a US independent speciality pharmacy, has been selected by Takeda Pharmaceuticals as an ultra-narrow limited distribution partner for MIMRYLO (rusfertide). The treatment is indicated for erythrocytosis in adults with polycythemia vera. MIMRYLO is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin. This inhibition reduces iron availability for red blood cell production, resulting in lower hematocrit levels. The drug's approval was based on the phase 3 VERIFY study, a global, randomised, open-label clinical trial. The primary endpoint measured the proportion of patients achieving response during weeks 20-32, defined as the absence of phlebotomy eligibility. The most common adverse reactions were injection site reactions at 56% and anaemia at 16%.

Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.